Richard Koya, MD, PhD of Roswell Park Cancer Institute gives an overview of his presentation, Sustained efficacy of immunotherapy for solid tumors with novel dual CD4/CD8 T cell receptor engineered synergistic combination of hematopoietic stem cells and T cells, which was presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.
Presentation Overview: Development of T-Cell Receptors Against NYESO-1 Targets
